Table 2 Multivariable Cox regression analysis, training cohort, n = 873, SOS/VOD included.

From: Early bilirubinemia after allogeneic stem cell transplantation—an endothelial complication

 

OS (events = 421)

NRM (events = 174)

TTR (events = 302)

PFS (events = 476)

 

HR

95% CI

p

CSHR

95% CI

p

CSHR

95% CI

p

HR

95% CI

p

EB

1.60

1.21–2.12

<0.001

2.14

1.28–3.56

0.004

0.95

0.65–1.40

0.803

1.46

1.11–1.91

0.006

Age (per year)

1.02

1.01–1.03

<0.001

1.04

1.02–1.05

<0.001

1.00

0.99–1.01

0.402

1.02

1.01–1.03

<0.001

Recipient sex

m vs. f

1.11

0.91–1.36

0.290

1.33

0.96–1.83

0.089

0.98

0.78–1.24

0.866

1.11

0.92–1.34

0.297

HLA mismatch

yes vs. no

1.40

1.11–1.78

0.005

1.78

1.24–2.56

0.002

1.16

0.87–1.55

0.308

1.34

1.07–1.68

0.011

MPN

yes vs. no

0.96

0.65–1.42

0.850

1.44

0.85–2.41

0.172

0.67

0.39–1.13

0.133

0.94

0.65–1.36

0.740

MTX

yes vs. no

0.76

0.61–0.95

0.018

0.66

0.46–0.95

0.023

0.84

0.65–1.09

0.183

0.74

0.60–0.91

0.005

ATG

vs. no ATG

0.73

0.59–0.91

0.004

0.57

0.40–0.80

0.001

0.79

0.62–1.02

0.069

0.78

0.63–0.95

0.015

RIC vs. MAC

0.75

0.57–0.97

0.027

0.73

0.49–1.10

0.133

0.78

0.57–1.06

0.106

0.75

0.58–0.96

0.020

  1. EB early bilirubinemia, OS overall survival, NRM non-relapse mortality, TTR time to relapse, PFS progression-free survival, HR hazard ratio, CSHR cause-specific hazard ratio, CI confidentiality interval, HLA human leukocyte antigen, HLA mismatch not matched in 10/10 alleles, AML acute myeloid leukemia, ATG anti-thymocyte globulin, RIC reduced intensity conditioning, MAC myeloablative conditioning, MPN myeloproliferative neoplasms, MTX methotrexate days 1, 3, 6, P values for NRM were corrected by 1000 bootstraps.
Back to article page